NCT03181399View on ClinicalTrials.gov

Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

September 10, 2023

Study Completion Date

September 10, 2023

Conditions
GLUT1DS1EpilepsyGlut1 Deficiency Syndrome 1, Autosomal RecessiveGlucose Metabolism DisordersGlucose Transport DefectGlucose Transporter Type 1 Deficiency SyndromeGlucose Transporter Protein Type 1 Deficiency Syndrome
Interventions
DRUG

Triheptanoin

. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Texas Southwestern Medical Center

OTHER

NCT03181399 - Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) | Biotech Hunter | Biotech Hunter